Drug Database
Back to search

Belgium· BE-AMP-SAM306171-00

Tandemact 45 mg - 4 mg

A glimepiride and pioglitazone product containing pioglitazone hydrochloride, registered in Belgium by Cheplapharm Arzneimittel. The same ATC class is registered in 10 of our 19 countries.

ATC A10BD06

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedTandemact 45 mg - 4 mgATCA10BD06REGISTER NO.BE-AMP-SAM306171-00PACKS LISTED0CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about pioglitazone hydrochlorideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Glimepiride and pioglitazone is registered in 10 of 19 countries.

Countries holding a registration under ATC A10BD06 (glimepiride and pioglitazone), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 7 of them publish a price we can compare per daily dose
Search glimepiride and pioglitazone products by name

Glimepiride and pioglitazone · ATC A10BD06

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Polandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Pioglitazone Hydrochloride
Manufacturer
Cheplapharm Arzneimittel
Country
Belgium (BE)
ATC code
A10BD06
ATC class
Glimepiride and pioglitazone
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

1 interaction on record for glimepiride and pioglitazone.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check glimepiride and pioglitazone against other medicinesHow interaction checks work

Glimepiride and pioglitazone · interactions on record

1 record

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Glimepiride and pioglitazone in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All glimepiride and pioglitazone products

Authorised across Europe · EMA

The same active substance is authorised in 18 EEA countries. Names it is sold under:

  • Bulgaria · Pioglitazone Sanovel, Пизона
  • Cyprus · Zipion
  • Czechia · Novapio, Pioglitazon Viatris
  • Germany · Pioglitazon Aurobindo
  • Spain · Pioglitazona Aurovitas, Pioglitazona Cinfa
  • United Kingdom (Northern Ireland) · Pioglitazone Brown And Burk Uk Ltd, Pioglitazone Generics
  • Greece · Glitact, Raglitan
  • Croatia · Novapio, Pioglitazon Pliva
  • Iceland · Actos, Pioglitazone Accord
  • Italy · Pioglitazone Aurobindo, Pioglitazone Doc Generici
  • Liechtenstein · Actos, Pioglitazone Accord
  • Latvia · Zipion
  • Malta · Novapio
  • Netherlands · Pioglitazone Hydrochloride Aurobindo, Pioglitazone Sanovel
  • Norway · Actos, Pioglitazone Accord
  • Poland · Pioglitazone Bioton
  • Portugal · Pioglitazona Atrolex, Pioglitazona Aurovitas
  • Sweden · Pioglitazone Holsten

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ebc5c1f0-3896-467e-9098-15435dbca6f4
GET /v1/drugs/ebc5c1f0-3896-467e-9098-15435dbca6f4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "source": "afmps",
  "status": "REVOKED",
  "name_en": "Tandemact 45 mg - 4 mg",
  "name_fr": "Tandemact 45 mg - 4 mg",
  "name_nl": "Tandemact 45 mg - 4 mg",
  "amp_code": "SAM306171-00",
  "strengths": [
    "45.0000",
    "45.0000",
    "4.0000",
    "4.0000",
    "45.0000"
  ],
  "pack_count": 6,
  "substances": [
    "Pioglitazone Hydrochloride",
    "Pioglitazone",
    "Glimepiride",
    "Lactose Monohydrate",
    "Polysorbate 80"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Glimepiride and Pioglitazone",
  "authorisation_numbers": [
    "EU/1/06/366/011",
    "EU/1/06/366/012",
    "EU/1/06/366/013",
    "EU/1/06/366/014",
    "EU/1/06/366/015",
    "EU/1/06/366/016"
  ]
}
API referenceMCP serverPlans

See everything about glimepiride and pioglitazone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console